(by Sven Gallasch) On 9 July 2014 the European Commission announced its decision to impose a fine of €427.7 million on French drug maker Servier and five generic companies in relation to so-called ‘pay for delay’ settlements concerning Servier’s bestselling blood pressure drug perindopril. The case differs from the Commission’s …read more Source: Global Competition Law Blogs
The EU Commission Decision against Servier – a New Dimension to European Pharmaceutical Antitrust? (ESRC Centre for Competition Policy)
by 21st Century Competition | Jul 11, 2014 | Global Blogs | 0 comments